文献速递瓣膜病与结构性心脏病

自膨胀经导管主动脉瓣系统用于高危症状性重度主动脉瓣狭窄患者

Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

CENTERA-2 关键研究在 23 个中心评估自膨胀镍钛合金经导管心脏瓣膜(THV)用于外科高危症状性重度主动脉瓣狭窄患者的安全性与有效性,203 例经股动脉植入,30 天全因死亡率为 1%,致残性卒中 2.5%,有效瓣口面积和跨瓣压差显著改善,永久起搏器植入率低。

要点

  • 30 天全因死亡率为 1%,致残性卒中为 2.5%。
  • 有效瓣口面积由 0.71±0.20 cm² 增至 1.88±0.43 cm²(p<0.001)。
  • 平均跨瓣压差由 40.5±13.2 mm Hg 降至 7.2±2.8 mm Hg(p<0.001)。

核心结论

  • 该自膨胀 THV 在外科高危症状性重度主动脉瓣狭窄患者中 30 天安全有效,死亡率低,血流动力学显著改善,不良事件发生率低,永久起搏器植入率尤其低。

研究设计与样本

  • 多中心关键研究,在 23 个中心完成经股动脉 THV 植入,纳入 203 例经心脏团队判定为外科高危的症状性重度主动脉瓣狭窄患者。
  • 临床与超声心动图结局在基线、出院和 30 天评估,主要事件由独立临床事件委员会裁定,超声和 CT 由核心实验室审阅。
  • 主要终点为 30 天全因死亡率。

主要发现

  • 患者年龄 82.7±5.5 岁,女性占 67.5%,NYHA 心功能 III/IV 级占 68.0%。
  • 30 天全因死亡率为 1%,致残性卒中发生率为 2.5%,NYHA I/II 级占 93.0%。
  • 有效瓣口面积从 0.71±0.20 cm² 增至 1.88±0.43 cm²(p<0.001),平均跨瓣压差从 40.5±13.2 mm Hg 降至 7.2±2.8 mm Hg(p<0.001)。
  • 30 天瓣周主动脉反流中度及以上占 0.6%,接受 THV 患者中新植入永久起搏器占 4.5%(高危患者中为 4.9%)。

临床怎么用

  • 对于外科高危的症状性重度主动脉瓣狭窄患者,可考虑使用该自膨胀 THV 行经股动脉植入,以改善血流动力学并降低 30 天死亡风险。
  • 该 THV 的永久起搏器植入率较低,在需要避免起搏器植入的患者中可能具有优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The CENTERA transcatheter heart valve (THV) is a low-profile, self-expanding nitinol valve made from bovine pericardial tissue that is 14-F compatible with a motorized delivery system allowing for repositionability. OBJECTIVES: The pivotal study evaluated safety and efficacy of this THV in high-surgical-risk study patients with severe symptomatic aortic stenosis. METHODS: Implantations were completed in 23 centers. Clinical and echocardiographic outcomes were assessed at baseline, discharge, and 30 days. Major events were adjudicated by an independent clinical events committee. Echocardiograms and computed tomography scans were reviewed by core laboratories. The primary endpoint was all-cause mortality at 30 days. RESULTS: Between March 25, 2015 and July 5, 2016, 203 patients with severe symptomatic aortic stenosis and increased surgical risk, as determined by the heart team, were treated by transfemoral THV implantation (age 82.7 ± 5.5 years, 67.5% female, 68.0% New York Heart Association functional class III/IV). At 30 days, mortality was 1%, disabling stroke occurred in 2.5% of patients, and New York Heart Association functional class I/II was observed in 93.0% of patients. Effective orifice area increased from 0.71 ± 0.20 cm2 to 1.88 ± 0.43 cm2 (p < 0.001). Mean aortic transvalvular gradient decreased from 40.5 ± 13.2 mm Hg to 7.2 ± 2.8 mm Hg at 30 days post-procedure (p < 0.001). Paravalvular aortic regurgitation at 30 days was moderate or higher in 0.6% of patients. A new permanent pacemaker was implanted in 4.5% of patients receiving the THV (4.9% for patients at risk). CONCLUSIONS: The herein described THV is safe and effective at 30 days with low mortality, significant improvements in hemodynamic outcomes, and low incidence of adverse events. Of particular interest is the low incidence of permanent pacemaker implantations. (Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reichenspurner H, Schaefer A, Schäfer U, et al. Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. J Am Coll Cardiol. 2017. PMID: 29268926. doi:10.1016/j.jacc.2017.10.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。